Aytu Biopharma (AYTU) Change in Receivables (2015 - 2026)

Aytu Biopharma (AYTU) has 12 years of Change in Receivables data on file, last reported at -$6.4 million in Q1 2026.

• On a quarterly basis, Change in Receivables fell 161.25% year-over-year to -$6.4 million in Q1 2026; TTM through Mar 2026 was -$11.3 million, a 272.62% decrease from a year earlier, with the FY2025 full-year figure at $7.6 million, up 246.68% from the prior year.
• Change in Receivables for Q1 2026 stood at -$6.4 million, down from -$2.3 million in the prior quarter.
• Over the last five years, Change in Receivables for AYTU reached as high as $10.5 million in Q1 2025 and fell as low as -$6.4 million in Q1 2026.
• Historically, Change in Receivables has averaged $92235.3 across 5 years, with a median of -$478000.0 in 2024.
• Across the five-year window, Change in Receivables sank 2775.45% in 2022 and surged 2025.42% in 2024, its largest moves.
• Year by year, Change in Receivables stood at -$2.4 million in 2022, then jumped by 95.04% to -$118000.0 in 2023, then jumped by 2025.42% to $2.3 million in 2024, then slumped by 201.32% to -$2.3 million in 2025, then sank by 179.5% to -$6.4 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were -$6.4 million in Q1 2026, -$2.3 million in Q4 2025, and $2.1 million in Q3 2025.